First patients test new cancer drug targeting specific tumor marker
NCT ID NCT05735366
Summary
This first-in-human study tested a new drug called SAIL66 in 22 patients with advanced solid tumors that have a specific marker called CLDN6. The main goals were to find a safe dose and see how the body processes the drug, while also checking for any early signs that it might help shrink tumors. This was an early safety study, so determining how well it works against cancer will require larger future trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234, United States
-
Cancer Institute Hospital of JFCR
Tokyo, Koto Ku, 135-8550, Japan
-
Georgia Cancer Center at Augusta University
Augusta, Georgia, 30912, United States
-
MUSC Hollings Cancer Center
Charleston, South Carolina, 29425, United States
-
National Cancer Center Hospital
Tokyo, Chuo Ku, 104-0045, Japan
-
National Cancer Center Hospital East
Kashiwa, Chiba, 277-8577, Japan
-
Shizuoka Cancer Center
Shizuoka, Sunto-gun, 411-8777, Japan
-
Tennessee Oncology, PLLC
Nashville, Tennessee, 37203, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.